Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit

Trials

Volumn 12, Issue , 2011, Pages

  Royston, Patrick ^a   Barthel, Friederike M S ^a   Parmar, Mahesh K B ^a   Choodari Oskooei, Babak ^a   Isham, Valerie ^b  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CLINICAL TRIAL (TOPIC); METHODOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; BIOASSAY; COMPUTER SIMULATION; DISEASE FREE SURVIVAL; EARLY TERMINATION OF CLINICAL TRIAL; HUMAN; MALE; MORTALITY; PROSTATE TUMOR; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS; TIME; TREATMENT OUTCOME;

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; EARLY TERMINATION OF CLINICAL TRIALS; ENDPOINT DETERMINATION; HUMANS; MALE; MEDICAL FUTILITY; MODELS, STATISTICAL; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; RESEARCH DESIGN; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952695574     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-81     Document Type: Article

References (20)

1. US Food and Drug Administration Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. US Dept of Health and Human Services 2004, US Food and Drug Administration.
2. Proschan MA, Lan KKG, Wittes J. Statistical Monitoring of Clinical Trials - A Unified Approach 2006, New York: Springer.
3. Armitage P, McPherson CK, Rowe BC. Repeated significance tests on accumulating data. Journal of the Royal Statistical Society, Series A 1969, 132:235-244.
4. Lan K, DeMets D. Discrete sequential boundaries for clinical trials. Biometrika 1983, 70:659-663.
5. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979, 35:549-556.
6. Pampallona S, Tsiatis A, Kim KM. Interim monitoring of group sequential trials using spending functions for the type I and II error probabilities. Drug Information Journal 2001, 35:1113-1121.
7. Royston P, Parmar MKB, Qian W. Novel designs for multi-arm clinical trials with survival outcomes, with an application in ovarian cancer. Statistics in Medicine 2003, 22:2239-2256. 10.1002/sim.1430, 12854091.
8. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, Geest KD, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. Journal of Clinical Oncology 2009, 27:1419-1425. 10.1200/JCO.2008.19.1684, 2668552, 19224846.
9. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, Dwyer J, Masters J, Parmar MKB. STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer - A Multi-Arm Multi-Stage Randomised Controlled Trial. Clinical Oncology 2008, 20:577-581. 10.1016/j.clon.2008.07.002, 18760574.
10. Tsiatis AA. The asymptotic joint distribution of the efficient scores test for the propor- tional hazards model calculated over time. Biometrika 1981, 68:311-315.
11. Betensky R. Construction of a continuous stopping boundary from an alpha spending function. Biometrics 1998, 54:1061-1071. 10.2307/2533857, 9750252.
12. Freidlin B, Korn EL, Gray R. A general inefficacy interim monitoring rule for randomized clinical trials. Clinical Trials 2010, 7:197-208. 10.1177/1740774510369019, 20423925.
13. Royston P, Wright EM. A method for estimating age-specific reference intervals ("normal ranges") based on fractional polynomials and exponential transformation. Journal of the Royal Statistical Society, Series A 1998, 161:79-101.
14. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 1989, 8:431-440. 10.1002/sim.4780080407, 2727467.
15. Barthel FMS, Babiker A, Royston P, Parmar MKB. Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over. Statistics in Medicine 2006, 25:2521-2542. 10.1002/sim.2517, 16479563.
16. Royston P, Parmar MKB. Flexible Parametric Proportional-Hazards and Proportional-Odds Models for Censored Survival Data, with Application to Prognostic Modelling and Estimation of Treatment Effects. Statistics in Medicine 2002, 21:2175-2197. 10.1002/sim.1203, 12210632.
17. Royston P. Flexible parametric alternatives to the Cox model, and more. Stata Journal 2001, 1:1-28.
18. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata Journal 2009, 9:265-290.
19. Posch M, Bauer P, Brannath W. Issues in Designing Flexible Trials. Statistics in Medicine 2003, 22:953-969. 10.1002/sim.1455, 12627412.
20. Cox DR, Isham V. Point Processes 1980, London: Chapman and Hall.